As of June 2026, ZTS's trailing twelve months (TTM) EPS stands at $6.04, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $6.03, which represents an increase compared to its EPS of $5.47 in 2024. ZTS reported an EPS of $1.42 for the quarterly report ending on Mar 31, 2026.
For 2025, Zoetis's EPS was $6.03, an increase of 10.2% from $5.47 in 2024. For the quarter ending Mar 31, 2026, the EPS was $1.42, showing a 6% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $6.04. In 2024, the annual EPS was $5.47, showing an increase of 7.7% from 2023.
Zoetis has recorded an increase in EPS of 6% over the last 12 months (YoY, quarterly). For the last three years, ZTS recorded an average annual EPS growth rate of 10.2%. Zoetis had an average annual EPS growth rate of 11.9% over the last 5 years. Across the last decade, ZTS had an average annual EPS growth of 24.4%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| ZTS Zoetis Inc | 12.72 | 10.2% | 10.2% | 11.9% |
| PAHC Phibro Animal Health Corp | 13.05 | 1,883.3% | -0.6% | 7.5% |
| PFE Pfizer Inc | 18.87 | -3.5% | -37.4% | -3.7% |
| MRK Merck & Co Inc | 33.5 | 8% | 8.4% | 21.2% |
| LLY ELI LILLY & Co | 39.27 | 95.6% | 49.2% | 27.5% |
| ICCC Immucell Corp | N/A | 53.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.